Arsenic trioxide sensitizes CD95/Fas‐induced apoptosis through ROS‐mediated upregulation of CD95/Fas by NF‐κB activation
CD95/Fas is a cell surface protein that belongs to the tumor necrosis factor receptor family. Signals through CD95/Fas are able to induce apoptosis in sensitive cells. Therefore, modalities to regulate the CD95/Fas expression level in tumor cells are called for. In the present study, we show that su...
Saved in:
Published in | International journal of cancer Vol. 112; no. 4; pp. 596 - 606 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
20.11.2004
Wiley-Liss |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | CD95/Fas is a cell surface protein that belongs to the tumor necrosis factor receptor family. Signals through CD95/Fas are able to induce apoptosis in sensitive cells. Therefore, modalities to regulate the CD95/Fas expression level in tumor cells are called for. In the present study, we show that sublethal doses of arsenic trioxide (As2O3) sensitized CD95/Fas‐induced apoptosis in human cervical cancer cells, and the sensitizing effects resulted from As2O3‐mediated increase in the expression of the CD95/Fas. N‐acetyl‐L‐cysteine, a specific scavenger of reactive oxygen species, abrogated As2O3‐induced upregulation of CD95/Fas and enhancement of CD95/Fas‐mediated apoptosis. Furthermore, inhibition of NF‐κB by transient transfection of IκBα supersuppressor blocked the increase of CD95/Fas expression following As2O3 treatment. Antisense oligonucleotide of CD95/Fas and ZB4, an antibody that blocks the binding of CD95/Fas ligand to CD95/Fas, reduced the amount of As2O3‐sensitized CD95/Fas‐induced apoptosis, demonstrating the specificity of CD95/Fas‐binding ligands in the As2O3‐sensitized CD95/Fas‐induced apoptosis. These findings demonstrate that sensitization of human cervical cancer cells to CD95/Fas‐mediated apoptosis by As2O3 can be partly due to induction of ROS and subsequent upregulation of CD95/Fas gene expression by NF‐κB activation. © 2004 Wiley‐Liss, Inc. |
---|---|
Bibliography: | The first 2 authors contributed equally to this paper. Fax: +82‐2‐970‐2402 |
ISSN: | 0020-7136 1097-0215 |
DOI: | 10.1002/ijc.20433 |